Why Corcept Therapeutics Incorporated’s (CORT) Stock Is Down 5.39%
As of Friday, July 31, Corcept Therapeutics Incorporated’s CORT share price has dipped by 5.39%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Stock Evaluator: Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated CORT
$110.77
2.82
2.61%
August 7, 2026 4:00:00 PM
EST
Volume: 769,036
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Corcept Therapeutics Incorporated’s (CORT) Stock Is Up 23.21%
As of Thursday, July 30, Corcept Therapeutics Incorporated’s CORT share price has surged by 23.21%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Corcept Therapeutics Incorporated’s (CORT) Stock Is Up 28.36%
As of Thursday, July 30, Corcept Therapeutics Incorporated’s CORT share price has surged by 28.36%, which has investors questioning if this is right time to sell.Tudor Pop
What You Need to Know About Corcept Therapeutics Incorporated's Q3 Earnings
Corcept Therapeutics Incorporated's fiscal Q3 earnings report was released on Wednesday, July 29. Let's dive in to see if (CORT) missed or beat analyst's expectations.Michael Rose
Is Corcept Therapeutics Incorporated (CORT) Overvalued?
We dive into why Corcept Therapeutics Incorporated (CORT) could be considered overvalued on 2026-07-23, based on AAII’s Value Score and Grade.Jenna Brashear
Financial Summary
| Share Statistics | CORT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11,974.1 | $620.4 | 79% |
|
| Shares Out (Mil) | 118.4 | 43.1 | 66% |
|
| Institutional Ownership | 86.8% | 84.4% | 55% |
|
| Float (Mil) | 90.7 | 47.1 | 59% |
|
| Beta | 0.46 | 0.64 | 26% |
|
| Avg Daily Volume (000s) | 1,543 | 304 | 76% |
|
| Price Change (52-week) |
57.1% | 67.3% | 81% |
|
| Growth | CORT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.6% | 6.7% | 76% |
|
| Net Income (5yr) | (1.2%) | (1.4%) | 38% |
|
| EPS (5yr) | (0.7%) | 14.9% | 30 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.9%) | (14.9%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.850 | $2.133 | $4.517 | |
| Month Ago EPS | $0.253 | $0.488 | $2.495 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.250 | $0.478 | $1.630 | |
| Year/Year Chg | 136.1% | 160.1% | 836.0% | |
| Financials | CORT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $831 | $275 | 48% |
|
| Net Income (TTM) (Mil) | $55 | ($11) | 56% |
|
| EPS (TTM) | $0.521 | ($0.600) | 54% |
|
| Operating Cash Flow (TTM) (Mil) | $110 | ($6) | 53% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $4 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $8 | $6 | 27% |
|
| Enterprise Value (Q1) (Mil) | $12,255 | $466 | 78% |
|
| Valuation | CORT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 16.94 | 2.92 | 94% |
|
| P/E | 244.0 | 20.0 | 98% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | CORT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 98.3% | 65.8% | 96% |
|
| Net Margin | 6.6% | 0.2% | 54% |
|
| ROA | 6.5% | (21.5%) | 78% |
|
| ROE | 8.2% | (16.0%) | 52% |
|
| Liabilities to Assets | 20.6% | 34.8% | 13% |
|
| F-Score | 4 | 3 | 34% |
|
Corcept Therapeutics Incorporated did not pass any screens on 8/7/2026.
